about
Microcirculation as determined by iontophoresis in SLE-patients and controls.Cardiovascular co-morbidity in patients with rheumatic diseases.Annexin A5 in cardiovascular disease and systemic lupus erythematosus.Gluten-free vegan diet induces decreased LDL and oxidized LDL levels and raised atheroprotective natural antibodies against phosphorylcholine in patients with rheumatoid arthritis: a randomized study.Genetic association of miRNA-146a with systemic lupus erythematosus in Europeans through decreased expression of the gene.Annexin A5 multitasking: a potentially novel antiatherothrombotic agent?Systemic lupus erythematosus and cardiovascular disease.Rheumatoid cachexia is associated with dyslipidemia and low levels of atheroprotective natural antibodies against phosphorylcholine but not with dietary fat in patients with rheumatoid arthritis: a cross-sectional studyImmune mechanisms in atherosclerosis, especially in diabetes type 2Low level natural antibodies against phosphorylcholine: a novel risk marker and potential mechanism in atherosclerosis and cardiovascular disease.Prediction and management of cardiovascular outcomes in systemic lupus erythematosus.Effect of biological therapy on levels of atheroprotective antibodies against phosphorylcholine and apolipoproteins in rheumatoid arthritis - a one year study.Effects of in vitro hyperthermia on proliferative responses and lymphocyte activity.Systemic lupus-erythematosus: deoxyribonuclease 1 in necrotic chromatin disposal.Heat shock proteins in cardiovascular disease and the prognostic value of heat shock protein related measurements.[Atherosclerosis not caused by overindulgence only. Infection may be a risk factor for cardiovascular disease]Health-related quality of life, fatigue and mood in patients with SLE and high levels of pain compared to controls and patients with low levels of pain.Antibodies against platelet-activating factor and platelet-activating factor-like lipids are raised in women with primary recurrent abortion.Risk factors for cardiovascular disease in patients with periodontitis.Decreased binding of annexin v to endothelial cells: a potential mechanism in atherothrombosis of patients with systemic lupus erythematosus.Non-traditional risk and protective factors for cardiovascular disease in systemic lupus erythematosus.PXK locus in systemic lupus erythematosus: fine mapping and functional analysis reveals novel susceptibility gene ABHD6.Low levels of IgM antibodies against phosphorylcholine-A potential risk marker for ischemic stroke in men.Natural antibodies against phosphorylcholine as potential protective factors in SLE.Oxidised LDL modulates immune-activation by an IL-12 dependent mechanism.Longitudinal levels of apolipoproteins and antibodies against phosphorylcholine are independently associated with carotid artery atherosclerosis 5 years after rheumatoid arthritis onset--a prospective cohort study.PCSK9 plays a novel immunological role in oxidized LDL-induced dendritic cell maturation and activation of T cells from human blood and atherosclerotic plaque.TNF-alpha: a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease.A 3'-untranslated region variant is associated with impaired expression of CD226 in T and natural killer T cells and is associated with susceptibility to systemic lupus erythematosus.Anti-high-density lipoprotein antibodies and lipoprotein characteristics in systemic lupus erythematosus-related cardiovascular disease.Association analysis with microsatellite and SNP markers does not support the involvement of BCL-2 in systemic lupus erythematosus in Mexican and Swedish patients and their familiesThe A-1087IL-10 allele is associated with cardiovascular disease in SLEAssociation of hypo-responsive toll-like receptor 4 variants with risk of myocardial infarction*1Dyslipidaemia and lipoprotein pattern in systemic lupus erythematosus (SLE) and SLE‐related cardiovascular diseaseDecreased binding of annexin V to endothelial cells: a novel mechanism of atherothrombosis in patients with systemic lupus erythematosusEndothelial function and activation in women with systemic lupus erythematosusAntibodies against lysophosphatidylcholine and oxidized LDL in patients with SLE[Non-therapeutic ventilation , organ transplantation and medical ethics][Organ donation and utilitarianism: medical ethics more important than medical efficiency]Cellular and cytokine characterization of vascular inflammation in CBA/J mice chronically infected with Trypanosoma cruzi
P50
Q34194913-E6BACD4D-28E0-4C6A-9143-F557A0486320Q35557796-3DBEBDC9-BA18-4471-8FCC-0362FE90F322Q36329969-E32D5972-CAD5-438B-BAC4-664B0AF0AE8BQ36757006-E9282415-7EC6-4860-9E3B-BB4387E99F37Q36806427-30C2D841-EBAD-4E15-BC77-3D270E05FC5AQ36945561-5162B783-6FB5-4652-877B-09A52D43F6B4Q37167995-DDF9A86A-E8B8-4187-81B0-E72C100F94A2Q37206912-8F18A74D-1DE2-4C21-8676-4ADE2DF415D7Q37261617-1E779A2D-5660-4333-B001-F1008B6AB889Q37596026-EAAABFA3-6393-47AB-B47C-B10E13BFD224Q38291820-4825C023-CEBE-489B-BEE7-3DB7FC30A695Q39677492-A6B71554-0CCB-44DA-87EA-DB4D438CC938Q40676148-44FEA6E1-2997-4213-8521-4379A8F21D60Q42487914-9E079F46-21E0-4D6E-AB10-68DCD5637FAAQ43012408-89498359-CD55-44EC-A913-4E2DCB6B526EQ43770532-271A5CFF-D609-4357-9B7D-28FCD2042243Q44300602-77B4659D-E960-4A2F-B176-9FD47629F30DQ44603389-2BE01A4B-99C5-42B6-9483-BD0E452705CAQ44672308-8EADFEF4-C4BD-4243-B6A5-1C669B52E05FQ45147984-9EAA6EB3-FB07-496F-B039-5E4A318B4485Q45966666-683CC643-55A7-42A6-A625-3B4C08D689EFQ46023783-CD32F014-894E-4B0A-ADE2-ECDC78C4FEC1Q46353070-DEF1ADD7-8A37-4536-9AA3-C42D29CA53C0Q46560299-065B34C4-941A-4D5B-9C52-2F9F6033FFB5Q47760929-E9BCD8B8-B9CB-45F7-82BC-B3576F73B9B3Q51549596-1B87A52B-4223-4BFF-8343-EBCD1ECAF9BAQ52607811-8A516EE3-C998-4D09-90EF-439477320E79Q53923210-DDDFC668-E8A6-489E-AE7A-3D773E27BEB8Q54417738-D69A0777-2E0F-40F7-81DD-A140D964B548Q55219707-1DCBA79E-43D2-4599-B7D8-3BB726BC8D8FQ57462040-D74DD26D-901F-4A0D-8059-AB2A85CECD43Q57537233-DF70A0F1-17EE-4BE3-84B6-6C8AF5F5BF9AQ57607713-F3DD08F2-BD47-4EB0-8AB0-DE3006CD93A4Q58190216-01E45B3C-44C1-4D10-B5F7-AFC293B739AAQ58190316-E80964E7-3E71-4FFC-902F-5364F55E10DFQ58190332-998FE12F-5CC3-48DB-A3EC-2BF4AE9F6B55Q58190403-AC1D6716-4A2B-4517-A138-D1FD02EF952BQ58661850-07E602DD-126D-4CA2-9AEC-1375F1DE28CAQ58664300-B409DA39-D9C2-4C01-95C5-4A381C16C8D9Q58842618-5E80A553-9768-4EE7-B97F-ECD98A80AA0E
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
研究者
@zh
name
J Frostegard
@ast
J Frostegard
@en
J Frostegard
@es
J Frostegard
@nl
type
label
J Frostegard
@ast
J Frostegard
@en
J Frostegard
@es
J Frostegard
@nl
prefLabel
J Frostegard
@ast
J Frostegard
@en
J Frostegard
@es
J Frostegard
@nl
P31
P496
0000-0002-3569-3367